There are currently 112 active clinical trials seeking participants for Dementia research studies. The states with the highest number of trials for Dementia participants are Florida, California, New York and Ontario.
Delirium Identification in Older Patients With Alzheimer's and Other Related Dementias In the Emergency Department
NCT06326424
Recruiting
Delirium is highly prevalent and very bad for patients with dementia. Delirium is a dangerous medical condition that occurs in 6-38% of older Emergency Department patients and 70% of ICU patients. A person who develops delirium in the ED or hospital has a 12 times higher odds of being newly diagnosed with dementia in the next year compared to a similar patient who does not become delirious. Delirium is especially dangerous for persons living with Alzheimer Disease and Related Dementias (AD/ADRD)... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/30/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Delirium, Dementia, Hospital Acquired Condition
Register for Updates
CONFIDENCE-AI Financial Education for Caregivers (CONFIDENCE-AI)
NCT06134180
Recruiting
The intervention being tested, CONFIDENCE-AI is a refined version of the original CONFIDENCE intervention made to reduce psychological financial strain and improve management of out-of-pocket care costs while increasing caregiver resourcefulness skills. Participants will be asked to participate in a 4-week intervention that includes participation in four, synchronous group-based Zoom sessions as well as between-session activities to apply learning. Participants will also receive tailored text me... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Alzheimer Disease, Dementia, Caregiver Burden, Financial Stress
Register for Updates
Learning Skills Together Family Caregiver Complex Intervention
NCT05846984
Recruiting
Learning Skills Together (LST) is a 6-week psychoeducational intervention focused on complex care (nursing) tasks completed by family caregivers to persons living with Alzheimer's Disease and related dementias. This study aims to test the efficacy of LST at reducing caregiver depression and negative appraisal of behavioral symptoms of dementia by building caregiver self-efficacy. To do this, eligible participants will be randomized into an intervention group (LST) or a control group condition fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Dementia, Alzheimer Disease, Caregiver Burden, Self Efficacy
Register for Updates
Genetic Characterization of Movement Disorders and Dementias
NCT02014246
Recruiting
Background: There are two basic types of movement disorders. Some cause excessive movement, some cause slowness or lack of movement. Some of these are caused by mutations in genes. On the other hand, dementia is a condition of declining mental abilities, especially memory. Dementia can occur at any age but becomes more frequent with age. Researchers want to study the genes of families with a history of movement disorders or dementia. They hope to find a genetic cause of these disorders. This ca... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/23/2025
Locations: National Institute of Aging, Clinical Research Unit, Baltimore, Maryland
Conditions: Dementia, Movement Disorder
Register for Updates
Coaching Dementia Caregivers to Master Care-Resistant Behavior
NCT05098652
Recruiting
266 family caregivers will be randomly assigned to either immediate intervention or delayed intervention groups. All caregivers will complete baseline surveys and 3 weeks of daily diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They will complete 3 rounds of 3-week daily diaries followed by an intermittent survey at 12 week intervals for the next 33 weeks. The delayed intervention group will receive 12 weeks of attention, complete 1 round of 3-week daily diaries follo... Read More
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
04/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Care-resistant Behavior, Dementia
Register for Updates
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/21/2025
Locations: Banner Alzheimer's Institute ( Site 0110), Phoenix, Arizona +48 locations
Conditions: Alzheimer Disease, Dementia
Register for Updates
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
NCT05374278
Recruiting
This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
04/16/2025
Locations: China Basin, UCSF, San Francisco, California
Conditions: Alzheimer Disease, Frontotemporal Dementia, Dementia
Register for Updates
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
NCT06919926
Recruiting
This randomized, crossover, placebo controlled clinical study will assess the efficacy and safety of a slow release form of levetiracetam (AGB101) in the treatment of cognitively normal adults by measuring change in several imaging measures over the course of a two week treatment period.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/15/2025
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Hippocampal Overactivity, Dementia
Register for Updates
Neurophysiological Benefits of Live Music for Early Alzheimer's Patients and Their Caregivers
NCT06940687
Recruiting
This study aims to investigate the neurophysiological effects of live music on individuals with early Alzheimer's Disease (AD), dementia, and/or mild cognitive impairment (MCI) and their caregivers. Heart rate (HR), heart rate variability (HRV), and brain activity will be measured as participant-caregiver dyads listen to preferred and improvised music performed by professional musicians. Investigators will leverage various measurement techniques including, but not limited to, electroencephalogra... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/15/2025
Locations: Firehouse 12 Studios, New Haven, Connecticut +1 locations
Conditions: Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Register for Updates
Connect-Home: Alzheimer's Disease and Related Dementias
NCT06840587
Recruiting
This study is a parallel arm, cluster randomized trial (CRT) to test the efficacy of Connect-Home ADRD, a transitional care intervention focusing on Skilled Nursing Facility (SNF) patients with Alzheimer's disease and dementias and their caregivers during transitions from SNFs to home, assisted, living, and long-term care. The primary hypothesis is that the intervention will reduce caregiver strain (Aim 1) and patient neuropsychiatric symptoms (Aim 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Alzheimer Disease, Dementia
Register for Updates
Investigating Dynamic Interactions in Distributed Cognitive Control Networks
NCT05927974
Recruiting
The purpose of this study is to investigate the brain activity associated with cognitive tasks (thinking, reasoning, remembering) in order to understand how the brain works during certain tasks and to improve treatment for diseases like dementia and attention deficit disorders. Cognitive (thinking) impairment may include poor memory function, poor attention span, or psychiatric disorders (ex: ADD, depression). The investigators are interested in the brain activity related to these issues, and wa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cognitive Impairment, Dementia, ADD, Depression
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 4
NCT05617014
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/09/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +54 locations
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
Register for Updates